Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 20.0-52.0,  Multiple Sclerosis, Relapsing-Remitting Diagnosis of Relapsing Remitting MS according to the 2017 revised McDonald OR one demyelinating episode in conjunction with at least one asymptomatic high intensity T2 lesion with size and location compatible with MS The patient has completed the trial and is treated with either of the study medications rituximab or DMF at the last visit of the trial OR has been treated with rituximab with a dose regimen of 500 mg followed by 500 mg every 6 months for up to two years as part of clinical practice Age 20 years (inclusive) EDSS 0 5 (inclusive) The patient is willing and able to give written informed consent, according to the judgement of the investigator In fertile females, willing to comply with effective contraceptive methods. These birth control pills, surgical sterilization of patient or partner or intrauterine device. Non-fertile women is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an FSH level in the postmenopausal range  Diagnosis of Progressive MS Previous treatment with any "second-line" immunomodulatory drug, eg natalizumab, alemtuzumab, fingolimod, or other long-acting immunosuppressive agents Pregnant or lactating women s-HCG will be tested on all women at screening, before each study-related infu-sion and in any situation where there is a reason to suspect pregnancy during the trial, e.g delayed menstrual period more than five days above expected time Patients having contraindication for or otherwise not compliant with MRI investigations Simultaneous treatment with other immunosuppressive drugs Active, severe infections Signs of infections are assessed before and each study-related infusion through clinical examination and further evaluated by laboratory and other relevant investigations in case of suspected ongoing infection. Hepatitis serology (HBsAg and anti-HBc) will be evaluated before treatment onset if not tested within the previous three years Severe cardiac disorder, e.g signs of congestive heart failure or coronary artery disease. This will be evaluated through clinical assessment before inclusion Vaccination within 4 weeks of first dose of study medication Documented allergy or intolerance to the IP Severe psychiatric condition